Have any thoughts about
Seagen Inc?
Write Note

Seagen Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Seagen Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
S
Seagen Inc
F:SGT
Stock-Based Compensation
$352.8m
CAGR 3-Years
32%
CAGR 5-Years
39%
CAGR 10-Years
28%
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$872m
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$739.3m
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Seagen Inc
Glance View

Market Cap
39.3B EUR
Industry
Biotechnology
Economic Moat
None

Seagen Inc., nestled in the vibrant Pacific Northwest, has carved out a formidable niche in the biotech arena with its relentless focus on oncology advancements. Born in 1997 as Seattle Genetics, this company has developed a reputation for its pioneering work in antibody-drug conjugates (ADCs). These innovative therapies are designed to deliver potent anti-cancer agents directly to tumor cells, minimizing damage to healthy tissues. Its flagship product, Adcetris, targets various Hodgkin’s lymphomas and has been instrumental in redefining treatment paradigms. This high-caliber development is not just a product of cutting-edge science, but of Seagen's strategic approach to partnerships and collaborations with other pharmaceutical giants, amplifying its research and market reach. Revenue for Seagen doesn't merely stem from its internal product pipeline; it also thrives on strategic alliances and licensing agreements. By engaging in collaborations with leading firms like Pfizer and Takeda, Seagen extends its influence beyond its direct sales, earning substantial sums from milestone payments and royalties as partners bring drugs to market. Furthermore, its business model is deeply entwined with a global vision, where navigating regulatory landscapes across different countries not only expands its market share but also its scientific influence. Seagen’s business strategy is a testament to how innovation in drug delivery mechanisms and thoughtful alliances can coalesce into a formidable presence in the biopharmaceutical industry, fueling both growth and a greater mission in the fight against cancer.

SGT Intrinsic Value
143.78 EUR
Overvaluation 31%
Intrinsic Value
Price
S

See Also

What is Seagen Inc's Stock-Based Compensation?
Stock-Based Compensation
352.8m USD

Based on the financial report for Sep 30, 2023, Seagen Inc's Stock-Based Compensation amounts to 352.8m USD.

What is Seagen Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
28%

Over the last year, the Stock-Based Compensation growth was 69%. The average annual Stock-Based Compensation growth rates for Seagen Inc have been 32% over the past three years , 39% over the past five years , and 28% over the past ten years .

Back to Top